Glutathione-responsive core cross-linked micelles for controlled cabazitaxel delivery

Han, Xiaoxiong; Gong, Feilong; Sun, Jing; Li, Yueqi; Liu, Xiaofei; Chen, Dan; Liu, Jianwen; Shen, Yue

doi:10.1007/s11051-018-4128-3

Cited by 16 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSH is a thiol‐containing tripeptide that plays a critical role in cell biology. According to reports in the literature, the concentration of GSH in tumor tissues and tumor cytosol (2–10 × 10 −3 m ) is at least fourfold higher than that in normal tissues, and the GSH‐rich tumor microenvironment can be used to realize stimuli‐responsive drug release and promote material degradation . Herein, we also explored the biodegradation of Ho‐HSN‐PEG in GSH solutions (5× 10 −3 and 10 × 10 −3 m ), which were prepared by dissolving the GSH in PBS solution (pH 7.4).…”

Section: Resultsmentioning

confidence: 99%

Functionalized Holmium‐Doped Hollow Silica Nanospheres for Combined Sonodynamic and Hypoxia‐Activated Therapy

Wang

Liu

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

The oxygen concentration dependence of sonodynamic therapy (SDT) and bioreductive therapy can be utilized to design the strategy of synergistic therapy. Herein, holmium-doped hollow silica nanospheres are synthesized and then sequentially modified with chlorin e6, carboxyl poly(ethylene glycol) silane, and prostate stem cell antigen (PSCA) monoclonal antibody. The resultant nanocomposite designated as HHSN-C/P-mAb has good biocompatibility and can specifically target cancer cells overexpressing PSCA. Due to the inner cavity structure and Ho doping, HHSN-C/P-mAb shows high ultrasound (US) imaging contrast capability and excellent high-field magnetic resonance contrast performance. HHSN-C/P-mAb can act as a nanocarrier for loading the bioreductive prodrug tirapazamine (TPZ), and the degradation of the hollow nanospheres under the trigger of acidic microenvironment favors the pH responsive release of TPZ from the material. Upon US irradiation, HHSN-C/P-mAb produces reactive oxygen species to kill the cancer cells, and importantly, the oxygen consumption during SDT induces an intratumoral hypoxic environment to activate the therapeutic function of codelivered TPZ, resulting in a high-effective synergistic therapy. The findings of this study highlight that HHSN-C/P-mAb is a versatile theranostic nanoplatform for efficient cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Functionalized Holmium‐Doped Hollow Silica Nanospheres for Combined Sonodynamic and Hypoxia‐Activated Therapy

Wang

Liu

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…The paclitaxel formulation Genexol‐PM developed in South Korea used the PEG‐b‐PLA polymer and achieved excellent clinical performance. Several studies have reported CTX‐loaded PLA polymer micelles (C. Feng et al, 2018; Han et al, 2016; Han, Gong, Chi, et al, 2018; Han, Gong, Sun, et al, 2018). Han et al conjugated a targeting polypeptide HM‐3 (IVRRADRAAVPGGGGRGD) (RGD containing) to PLA–PEG copolymer, and formed mPEG‐PLA‐(LA) 4 micelles and loaded CTX in the self‐assembled micelles (Han, Gong, Chi, et al, 2018).…”

Section: The Development Of Cabazitaxel Formulationsmentioning

confidence: 99%

Current development of cabazitaxel drug delivery systems

Sun

Lovell

Zhang

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The second-generation taxane cabazitaxel has been clinically approved for the treatment of metastatic castration-resistant prostate cancer after docetaxel failure. Compared with the first-generation taxanes paclitaxel and docetaxel, cabazitaxel has potent anticancer activity and is less prone to drug resistance due to its lower affinity for the P-gp efflux pump. The relatively high hydrophobicity of cabazitaxel and the poor aqueous colloidal stability of the commercial formulation, following its preparation for injection, presents opportunities for new cabazitaxel formulations with improved features. This review provides an overview of cabazitaxel drug formulations and hydrophobic taxane drug delivery systems in general, and particularly focuses on emerging cabazitaxel delivery systems discovered in the past 5 years.

show abstract

“…Many nanocarriers have been designed based on this mechanism. Han et al used lipoic acid-grafted poly(ethylene glycol)block-poly(D,L-lactic acid) (PEG-b-PLA) to prepare disulfide-crosslinked GSH-responsive cabazitaxel micelles (DCL-CTX micelles) [87]. The in vitro release test demonstrated that the DCL-CTX micelles remained stable in the medium without GSH, but released the drug in the medium containing GSH (10 mM).…”

Section: Polymeric Micellesmentioning

confidence: 99%

Recent progress in nanoformulations of cabazitaxel

Chen

Pan

et al. 2021

Biomed. Mater.

View full text Add to dashboard Cite

The antitumor efficacy of various paclitaxel (PTX) and docetaxel (DTX) formulations in clinical applications is seriously affected by drug resistance. Cabazitaxel, a second-generation taxane, exhibits greater anticancer activity than PTX and DTX and has low affinity for the P-glycoprotein efflux pump because of its structure. Therefore, cabazitaxel has the potential to overcome taxane resistance. However, owing to the high systemic toxicity and hydrophobicity of cabazitaxel and the instability of its commercial preparation, Jevtana®, the clinical use of cabazitaxel is restricted to patients with metastatic castration-resistant prostate cancer who show progression after DTX-based chemotherapy. Nanomedicine is expected to overcome the limitations associated with cabazitaxel application and surmount taxane resistance. This review outlines the drug delivery systems of cabazitaxel published in recent years, summarizes the challenges faced in the development of cabazitaxel nanoformulations, and proposes strategies to overcome these challenges.

show abstract

Glutathione-responsive core cross-linked micelles for controlled cabazitaxel delivery

Cited by 16 publications

References 42 publications

Functionalized Holmium‐Doped Hollow Silica Nanospheres for Combined Sonodynamic and Hypoxia‐Activated Therapy

Functionalized Holmium‐Doped Hollow Silica Nanospheres for Combined Sonodynamic and Hypoxia‐Activated Therapy

Current development of cabazitaxel drug delivery systems

Recent progress in nanoformulations of cabazitaxel

Contact Info

Product

Resources

About